Molecular dynamics simulations of HIV-1 protease suggest different mechanisms contributing to drug resistance

Journal of Chemical Theory and Computation

Volumn 1, Issue 2, 2005, Pages 315-324

  Wartha, Florian ^a   Horn, Anselm H C ^a   Meiselbach, Heike ^a   Sticht, Heinrich ^a  

^a UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 25844449712     PISSN: 15499618     EISSN: 15499626     Source Type: Journal    
DOI: 10.1021/ct049869o     Document Type: Article

References (63)

1. UNAIDS/WHO 2004 Report on the global AIDS epidemic; 2004.
2. Kohl, N. E.; Emmi, E. A.; Schleif, W. A.; Davies, L. J.; Heimbach, J. C.; Dixon, R. A. F. Active human immunodeciency virus protease is required for viral infectivity. Proc. Natl. Acad. Sci. 1988, 85, 686-690.
3. Katoh, I.; Yasunaga, T.; Ikawa, Y.; Yoshinaka, Y. Inhibition of retroviral protease activity by an aspartyl proteinase inhibitor. Nature 1987, 329, (6140), 654-6.
4. Stephenson, J. The art of 'HAART': researchers probe the potential and limits of aggressive HIV treatments. Jama 1997, 277, (8), 614-6.
5. Voelker, R. The world in medicine: HIV drug resistance. Jama 2000, 284, (2), 169.
6. Shafer, R. W. Genotypic testing for human immunodeficiency virus type 1 drug resistance. Clin. Microbiol. Rev. 2002, 15, (2), 247-77.
7. Draghici, S.; Potter, R. B. Predicting HIV drug resistance with neural networks. Bioinformatics 2003, 19, (1), 98-107.
8. Piana, S.; Carloni, P.; Röthlisberger, U. Drug resistance in HIV-1 protease: Flexibility-assisted mechanism of compensatory mutations. Protein Sci. 2002, 11, (10), 2393-402.
9. Muzammil, S.; Ross, P.; Freire, E. A major role for a set of nonactive site mutations in the development of HIV-1 protease drug resistance. Biochemistry 2003, 42, (3), 631-8.
10. Walter, H.; Schmidt, B.; Korn, K.; Vandamme, A. M.; Harrer, T.; Uberla, K. Rapid, phenotypic HIV-1 drug sensitivity assay for protease and reverse transcriptase inhibitors. J. Clin. Virol. 1999, 13, (1-2), 71-80.
11. Martinez-Picado, J.; Savara, A. V.; Shi, L.; Sutton, L.; D'Aquila, R. T. Fitness of human immunodeficiency virus type 1 protease inhibitor-selected single mutants. Virology 2000, 275, (2), 318-22.
12. Schmidt, B.; Walter, H.; Moschik, B.; Paatz, C.; van Vaerenbergh, K.; Vandamme, A. M.; Schmitt, M.; Harrer, T.; Uberla, K.; Korn, K. Simple algorithm derived from a geno-/phenotypic database to predict HIV-1 protease inhibitor resistance. Aids 2000, 14, (12), 1731-8.
13. Schinazi, R. F.; Larder, B.; Mellors, J. W. Mutations in retroviral genes associated with drug resistance: 2000-2001 update. Int. AntiVir. News 2000, 8, 65-92.
14. Blaise, P.; Clevenbergh, P.; Vaira, D.; Moutschen, M.; Dellamonica, P. HIV resistance to antiretroviral drugs: mechanisms, genotypic and phenotypic resistance testing in clinical practice. Acta Clin. Belg. 2002, 57, (4), 191-201.
15. Perryman, A. L.; Lin, J. H.; McCammon, J. A. HIV-1 protease molecular dynamics of a wild-type and of the V82F/I84V mutant: possible contributions to drug resistance and a potential new target site for drugs. Protein Sci. 2004, 13, (4), 1108-23.
16. Chen, X.; Weber, I. T.; Harrison, R. W. Molecular dynamics simulations of 14 HIV protease mutants in complexes with indinavir. J. Mol. Model. (Online) 2004, 10, (5-6), 373-81.
17. Markowitz, M.; Conant, M.; Hurley, A.; Schluger, R.; Duran, M.; Peterkin, J.; Chapman, S.; Patick, A.; Hendricks, A.; Yuen, G. J.; Hoskins, W.; Clendeninn, N.; Ho, D. D. A preliminary evaluation of nelfinavir mesylate, an inhibitor of human immunodeficiency virus (HIV)-1 protease, to treat HIV infection. J. Infect. Dis. 1998, 177, (6), 1533-40.
18. Petropoulos, C. J.; Parkin, N. T.; Limoli, K. L.; Lie, Y. S.; Wrin, T.; Huang, W.; Tian, H.; Smith, D.; Winslow, G. A.; Capon, D. J.; Whitcomb, J. M. A novel phenotypic drug susceptibility assay for human immunodeficiency virus type 1. Antimicrob. Agents Chemother. 2000, 44, (4), 920-8.
19. Ziermann, R.; Limoli, K.; Das, K.; Arnold, E.; Petropoulos, C. J.; Parkin, N. T. A mutation in human immunodeficiency virus type 1 protease, N88S, that causes in vitro hypersensitivity to amprenavir. J. Virol. 2000, 74, (9), 4414-9.
20. Patick, A. K.; Duran, M.; Cao, Y.; Shugarts, D.; Keller, M. R.; Mazabel, E.; Knowles, M.; Chapman, S.; Kuritzkes, D. R.; Markowitz, M. Genotypic and phenotypic characterization of human immunodeficiency virus type 1 variants isolated from patients treated with the protease inhibitor nelfinavir. Antimicrob. Agents Chemother. 1998, 42, (10), 2637-44.
21. Berman, H. M.; Westbrook, J.; Feng, Z.; Gilliland, G.; Bhat, T. N.; Weissig, H.; Shindyalov, I. N.; Bourne, P. E. The Protein Data Bank. Nucleic Acids Res. 2000, 28, (1), 235-42.
22. Kim, E. E.; Baker, C. T.; Dwyer, M. D.; Murcko, M. A.; Rao, B. G.; Tung, R. D.; Navia, M. A. Crystal Structure of HIV-1 Protease in Complex with VX-478, a potent and orally bioavailable Inhibitor of the Enzyme. J. Am. Chem. Soc. 1995, 117, 1181-1182.
23. Kaldor, S. W.; Kalish, V. J.; Davies, J. F., II.; Shetty, B. V.; Fritz, J. E.; Appelt, K.; Burgess, J. A.; Campanale, K. M.; Chirgadze, N. Y.; Clawson, D. K.; Dressman, B. A.; Hatch, S. D.; Khalil, D. A.; Kosa, M. B.; Lubbehusen, P. P.; Muesing, M. A.; Patick, A. K.; Reich, S. H.; Su, K. S.; Tatlock, J. H. Viracept (nelfinavir mesylate, AG1343): a potent, orally bioavailable inhibitor of HIV-1 protease. J Med. Chem. 1997, 40, (24), 3979-85.
24. Miller, M.; Schneider, J.; Sathyanarayana, B. K.; Toth, M. V.; Marshall, G. R.; Clawson, L.; Selk, L.; Kent, S. B.; Wlodawer, A. Structure of complex of synthetic HIV-1 protease with a substrate-based inhibitor at 2.3 A resolution. Science 1989, 246, (4934), 1149-52.
25. Kurt, N.; Scott, W. R.; Schiffer, C. A.; Haliloglu, T. Cooperative fluctuations of unliganded and substrate-bound HIV-1 protease: a structure-based analysis on a variety of conformations from crystallography and molecular dynamics simulations. Proteins 2003, 51, (3), 409-22.
26. Dolezal, O.; De Gori, R.; Walter, M.; Doughty, L.; Hattarki, M.; Hudson, P. J.; Kortt, A. A. Single-chain Fv multimers of the anti-neuraminidase antibody NC10: the residue at position 15 in the V (L) domain of the scFv-0 (V (L)-V (H)) molecule is primarily responsible for formation of a tetramertrimer equilibrium. Protein Eng. 2003, 16, (1), 47-56.
27. Chen, Y. Z.; Gu, X. L.; Cao, Z. W. Can an optimization/scoring procedure in ligand-protein docking be employed to probe drug-resistant mutations in proteins? J. Mol. Graph. Model. 2001, 19, 450-570.
28. Tripos Sybyl 6.9, Release 7.0A., St. Louis, Missouri, USA, 1991-2002.
29. Ratner, L.; Haseltine, W.; Patarca, R.; Livak, K. J.; Starcich, B.; Josephs, S. F.; Doran, E. R.; Rafalski, J. A.; Whitehorn, E. A.; Baumeister, K.; et al. Complete nucleotide sequence of the AIDS virus, HTLV-III. Nature 1985, 313, (6000), 277-84. (Pubitemid 15151982)
30. Tie, Y.; Boross, P. I.; Wang, Y. F.; Gaddis, L.; Hussain, A. K.; Leshchenko, S.; Ghosh, A. K.; Louis, J. M.; Harrison, R. W.; Weber, I. T. High-resolution crystal structures of HIV-1 protease with a potent non-peptide inhibitor (UIC-94017) active against multi-drug-resistant clinical strains. J. Mol. Biol. 2004, 338, (2), 341-52.
31. Smith, R.; Brereton, I. M.; Chai, R. Y.; Kent, S. B. Ionization states of the catalytic residues in HIV-1 protease. Nat. Struct. Biol. 1996, 3, (11), 946-50.
32. Thomson, M. A. Arguslab 3.1, Planaria Software LLC: Seattle, WA, 2004.
33. Rappé, A. K.; Casewit, C. J.; Colwell, K. S.; Goddard, W. A. I.; Skiff, W. M. UFF, a Rule-Based Full Periodic Table Force Field for Molecular Mechanics and Molecular Dynamics Simulations. J. Am. Client. Soc. 1992, 114, 10024-10035.
34. Dewar, M. J. S.; Zoebisch, E. G.; Healy, E. F.; Stewart, J. J. P. AM1: A New General Purpose Quantum Mechanical Molecular Model. J. Am. Client. Soc. 1985, 107, 3902-3909.
35. Clark, T.; Alex, A.; Beck, B.; Burkhardt, F.; Chandrasekhar, J.; Gedeck, P.; Horn, A. H. C.; Hutter, M.; Martin, B.; Rauhut, G.; Sauer, W.; Schindler, T.; Steinke, T. Vamp 8.1 B33, Erlangen, 2000-2004.
36. Frisch, M. J.; Trucks, G. W.; Schlegel, H. B.; Scuseria, G. E.; Robb, M. A.; Cheeseman, J. R.; Zakrzewski, V. G.; Montgomery, J. A., Jr.; Stratmann, R. E.; Burant, J. C.; Dapprich, S.; Millam, J. M.; Daniels, A. D.; Kudin, K. N.; Strain, M. C.; Farkas, O.; Tomasi, J.; Barone, V.; Cossi, M.; Cammi, R.; Mennucci, B.; Pomelli, C.; Adamo, C.; Clifford, S.; Ochterski, J.; Petersson, G. A.; Ayala, P. Y.; Cui, Q.; Morokuma, K.; Malick, D. K.; Rabuck, A. D.; Raghavachari, K.; Foresman, J. B.; Cioslowski, J.; Ortiz, J. V.; Baboul, A. G.; Stefanov, B. B.; Liu, G.; Liashenko, A.; Piskorz, P.; Komaromi, I.; Gomperts, R.; Martin, R. L.; Fox, D. J.; Keith, T.; Al-Laham, M. A.; Peng, C. Y.; Nanayakkara, A.; Gonzalez, C.; Challacombe, M.; Gill, P. M. W.; Johnson, B.; Chen, W.; Wong, M. W.; Andres, J. L.; Gonzalez, C.; Head-Gordon, M.; Replogle, E. S.; Pople, J. A. Gaussian 98, Revision A.11.3, Gaussian Inc.: Pittsburgh, PA, 1998.
37. Bayly, C. I.; Cieplak, P.; Cornell, W. D.; Kollman, P. A. A well-behaved electrostatic potential based method using charge restraints for deriving atomic charges: the RESP model. J. Phys. Chem. 1993, 97, 10269-10280.
38. Cornell, W. D.; Cieplak, P.; Bayly, C. I.; Kollman, P. A. Application of RESP charges to calculate conformational energies, hydrogen bond energies and free energies of solvation. J. Am. Chem. Soc. 1993, 115, 9620-9631.
39. Pearlman, D. A.; Case, D. A.; Caldwell, J. W.; Ross, W. S.; Cheatham, T. E., III.; DeBolt, S.; Ferguson, D.; Seibel, G.; Kollman, P. AMBER, a package of computer programs for applying molecular mechanics, normal-mode analysis, molecular dynamics and free energy calculations to simulate the structural and energetic properties of molecules. Comput. Phys. Commun. 1995, 91, 1-41.
40. Cornell, W. D.; Cieplak, P.; Bayly, C. I.; Gould, I. R.; Merz, K. M. J.; Ferguson, D. M.; Spellmeyer, D. C.; Fox, T.; Caldwell, J. W.; Kollman, P. A. A Second Generation Force Fiel for the Simulaton of Proteins, Nucleic Acids and Organic Molecules. J. Am. Chem. Soc. 1995, 117, 5179-5197.
41. Cheatham, T. E., III.; Cieplak, P.; Kollman, P. A. A modified version of the Cornell et al. force field with improved sugar pucker phases and helical repeat. J. Biomol. Struct. Dyn. 1999, 16, (4), 845-62.
42. Wang, J.; Wolf, R. M.; Caldwell, J. W.; Kollman, P. A.; Case, D. A. Development and testing of a general amber force field. J. Comput. Chem. 2004, 25, (9), 1157-74.
43. Jorgensen, W. L.; Chandrasekhar, J.; Madura, J. D.; Impey, R. W.; Klein, M. L. Comparison of simple potential functions for simulating liquid water. J. Chem. Phys. 1983, 79, 926-935.
44. Darden, T. A.; York, D. M.; Pedersen, L. G. Particle mesh Ewald. An N.log (N) method for Ewald sums in large systems. J. Chem. Phys. 1993, 98, 10089-10092.
45. Ryckaert, J. P.; Ciccotti, G.; Berendsen, H. J. C. Numerical integration of the Cartesian equations of motion of a system with constraints: molecular dynamics of n-alkanes. J. Comput. Phys. 1977, 23, 327-341.
46. Sayle, R. A.; Milner-White, E. J. RASMOL: biomolecular graphics for all. Trends Biochem. Sci. 1995, 20, (9), 374.
47. MDL ISIS/Draw 2.3., San Leandro, CA, 1990-2000.
48. Brünger, A. T. XPLOR, version 3.1. A system for X-ray crystallography and NMR. Yale UniVersity Press: New HaVen, CT 1992.
49. Lepsik, M.; Kriz, Z.; Havlas, Z. Efficiency of a secondgeneration HIV-1 protease inhibitor studied by molecular dynamics and absolute binding free energy calculations. Proteins 2004, 57, (2), 279-93.
50. Zoete, V.; Michielin, O.; Karplus, M. Relation between sequence and structure of HIV-1 protease inhibitor complexes: a model system for the analysis of protein flexibility. J. Mol. Biol. 2002, 315, (1), 21-52.
51. Wang, W.; Kollman, P. A. Computational study of protein specificity: the molecular basis of HIV-1 protease drug resistance. Proc. Natl. Acad. Sci. U. S. A. 2001, 98, (26), 14937-42.
52. Tsai, C. J.; Ma, B.; Nussinov, R. Folding and binding cascades: shifts in energy landscapes. Proc. Natl. Acad. Sci. U. S. A. 1999, 96, (18), 9970-2.
53. Luque, I.; Freire, E. Structural stability of binding sites: consequences for binding affinity and allosteric effects. Proteins 2000, Suppl 4, 63-71.
54. Sinha, N.; Nussinov, R. Point mutations and sequence variability in proteins: redistributions of preexisting populations. Proc. Natl. Acad. Sci. U. S. A. 2001, 98, (6), 3139-44.
55. Davis, A.; Teague, S. Hydrogen bonding, hydrophobic interactions, and failure of the rigid receptor hypothesis. Angew. Client. Int. Ed. Engl. 1999, 38, 736-749. (Pubitemid 29146588)
56. Rauh, D.; Klebe, G.; Stubbs, M. T. Understanding proteinligand interactions: the price of protein flexibility. J. Mol. Biol. 2004, 335, (5), 1325-41.
57. Engh, R. A.; Brandstetter, H.; Sucher, G.; Eichinger, A.; Baumann, U.; Bode, W.; Huber, R.; Poll, T.; Rudolph, R.; von der Saal, W. Enzyme flexibility, solvent and 'weak' interactions characterize thrombin-ligand interactions: implications for drug design. Structure 1996, 4, (11), 1353-62.
58. Prade, L.; Engh, R. A.; Girod, A.; Kinzel, V.; Huber, R.; Bossemeyer, D. Staurosporine-induced conformational changes of cAMP-dependent protein kinase catalytic subunit explain inhibitory potential. Structure 1997, 5, (12), 1627-37.
59. Brzozowski, A. M.; Pike, A. C.; Dauter, Z.; Hubbard, R. E.; Bonn, T.; Engstrom, O.; Ohman, L.; Greene, G. L.; Gustafsson, J. A.; Carlquist, M., Molecular basis of agonism and antagonism in the oestrogen receptor. Nature 1997, 389, (6652), 753-8.
60. Urzhumtsev, A.; Tete-Favier, F.; Mitschler, A.; Barbanton, J.; Barth, P.; Urzhumtseva, L.; Biellmann, J. F.; Podjarny, A.; Moras, D. A 'specificity' pocket inferred from the crystal structures of the complexes of aldose reductase with the pharmaceutically important inhibitors tolrestat and sorbinil. Structure 1997, 5, (5), 601-12.
61. Ferreon, J. C.; Hilser, V. J. Ligand-induced changes in dynamics in the RT loop of the C-terminal SH3 domain of Sem-5 indicate cooperative conformational coupling. Protein Sci. 2003, 12, (5), 982-96.
62. Clemente, J. C.; Moose, R. E.; Hemrajani, R.; Whitford, L. R.; Govindasamy, L.; Reutzel, R.; McKenna, R.; Agbandje-McKenna, M.; Goodenow, M. M.; Dunn, B. M. Comparing the accumulation of active-and nonactive-site mutations in the HIV-1 protease. Biochemistry 2004, 43, (38), 12141-51.
63. Mahalingam, B.; Wang, Y. F.; Boross, P. I.; Tozser, J.; Louis, J. M.; Harrison, R. W.; Weber, I. T. Crystal structures of HIV protease V82A and L90M mutants reveal changes in the indinavir-binding site. Eur. J. Biochem. 2004, 271, (8), 1516-24.